To maybe give a bit of history on lambda-cyhalothrin, a re-evaluation happened. In the first consultation we were basically proposing to cancel all uses. We sought more information, as we typically do during a consultation. We also asked the company to prioritize the use. The risk was dietary in nature, for children in particular, in terms of the amount consumed every day or over a lifetime. The company prioritized the list of crops that would make it to the label. If the first one passes, we add it, and so on and so forth. The company did not identify feed as a priority. Hence, the decision allowed more uses on the label, but the feed did not make it, because the company did not identify it as a priority for them.
That being said, the company has now provided us with an application to revisit the decision with new information. We're in the middle of reviewing that information.